An investigational stem cell-based therapy that would replace the nerve cells, or neurons, lost due to Parkinson’s disease was found to be generally safe and feasible for use after one year of study in a first-in-human clinical trial — results the researchers say support the treatment’s continued clinical development.

Kenai Therapeutics has completed patient enrollment in a small, early clinical trial testing the safety and effectiveness of RNDP-001, its direct-to-the-brain cell therapy for treating an underlying cause of Parkinson’s disease. The Phase 1b/2a REPLACE trial (NCT07106021), now underway at three sites in the U.S., has recruited…

National Football League players had nearly four times the expected mortality rate from neurodegenerative diseases, including Parkinson’s disease, despite having lower overall mortality than the general population, a large study found. Researchers at Mass General Brigham, Boston University, and the Concussion & CTE Foundation conducted the study, which included nearly…

A few weeks ago, my husband, John, and I were at a friend’s house for dinner. It was a delightful evening of dining al fresco, delicious food, and friends in a beautiful environment. There was only one problem: I couldn’t hear the conversation! Ack! I’ve known for years that I…

Aspen Neuroscience has completed dosing in the third and fourth groups of people with Parkinson’s disease receiving its new commercial-ready formulation of the cell therapy sasineprocel (ANPD001) in a small U.S. clinical trial. This brings the total number of adults with Parkinson’s who received sasineprocel in the…